T-Cell Replete Peripheral Blood Stem Cell Transplantation after Non-Myeloablative Conditioning with Post-Transplant High Dose Cyclophosphamide Is Safe and Is Associated with Acceptable Outcomes  by Bhamidipati, Pavan Kumar et al.
Abstracts / Biol Blood Marrow Transplant 20 (2014) S27eS44 S29requiring therapy (14.38 vs. 12.00 per 1000 pt day, p¼0.03)
between post-transplant days 46-180, the period when pts
with GVHD are on systemic immunosuppression. The most
frequent bacterial infections were staphylococcus (n¼ 129),
enterococcus (n¼56), clostridium difﬁcile (n¼42), pseudo-
monas (n¼18), mycobacterium (n¼9), and others (n¼54). In
contrast, MMF dose had no impact on speciﬁc infection types
at post-transplant days 0-45 and days 181-365. Additionally,
MMF dose was not an independent predictor of treatment
related mortality at 6 months (RR 1.38, 95%CI 0.91-2.10,
p¼0.13), or 2-year post-transplant disease relapse (RR 1.08,
95%CI 0.74-1.59, p¼0.69), disease free survival (RR 1.17, 95%CI
0.89-1.53, p¼0.26), or overall survival (RR 1.27, 95%CI 0.94-
1.72, p¼0.12). Infection related mortality rate was similar
between two groups (14% MMF 2g vs. 16% MMF 3g, p¼0.55).
Our data indicates that MMF 3g/day dosing reduces the risk
of acute GVHD without increasing the risk of infectious
complications and it should be used for GVHD prophylaxis
following dUCBT.10
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Introduction: Multiple approaches have been made to
minimize graft versus host disease (GvHD) after allogeneicFigure 1a. Overall survival (OS) rates and Figure 1b. Relapse-free survival (RFS) rates
who were in remission (dark line) at the time of their transplant.hematopoietic cell transplantation (allo-HCT) without
compromising graft versus leukemia (GvL) effect. Use of high
dose cyclophosphamide in the early post-transplant period
(PT-Cy) has signiﬁcantly improved the outcomes of allo-HCT
and encouraging results using this regimen have been
recently reported in both haploidentical and non-hap-
loidentical transplant setting (Bashey et al JCO, 2013, Fuchs et
al, Blood, 2010). However, so far the use of peripheral blood
stem cells (PBSC) with non-myeloablative (NMA) conditioning
PT-Cy has not been reported in literature.
Patients and methods: A total of 21 patients (median age
45 (22-74) years, 12 males and 9 females) between July 2009
and June 2013 underwent allo-HCT on this regimen. The
NMA conditioning consisted of Fludarabine (30mg/m2/day
on days -6 to -2), Cyclophosphamide (14.5 mg/kg/day on D -6
and -5) and TBI (200cGy on D -1) and Cyclophosphamide
(50mg/kg-bw on D +3 and D +4). PBSC was used a graft
source with a median CD34+ count of 5 x 106/kg-bw and
CD3+ T cell dose of 19.7 x 107/kg-bw. GvHD prophylaxis
included MMF plus Tacrolimus. Median follow-up for the
patients was 235 (17-1174) days. Diagnosis of the patients
included AML (n¼14), ALL (n¼2), CML (n¼1), NHL (n¼2), CLL
(n¼1) and Aplastic anemia (n¼1). 10 out of 21 patients un-
derwent transplant in active disease and 4 of these patients
had prior history of allo-HCT.
Results: 19 patients (95%) engrafted with median neutrophil
engraftment on day 15 (12-28) days and median platelet
engraftment on day 16 (11-40) days. None of these patients
had secondary graft failure. 1 year over all survival rates (OS)
of 57% were encouraging. The 1-year OS for those underwent
transplant with active disease and in remissionwere 63% and
56% respectively (Figure 1a). 1-year relapse free survival
(RFS) was 56% for those who underwent transplant in
remission and 41% in those who underwent transplant in
active disease (Figure 1b). 100 day and 1-year NRM rates
were 9.5% and 14% respectively. Cumulative incidence of
aGvHD at 2 months and 90 days was 38% and 47% respec-
tively (grade III-IV in 4 patients). Cumulative incidence of
cGvHD at 1 and 2 years were both at 12% (extensive in 1
patient). CMV reactivation occurred in 14 patients (66%)
without the development of CMV disease.
Conclusions: Herewe report for the ﬁrst time the results of a
novel regimen combining NMA conditioning with T-cell
replete G-CSF mobilized PBSC for allo-HCT with high dosein patients after allo-HCT, patients with active disease (dashed line), patients
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rates, encouraging survival rates and very low grade III-IV
aGvHD and extensive cGVHD rates despite relatively high T
cells doses. The results from this relatively small number of
mostly high-risk patients are encouraging and form basis for
testing it in a larger cohort of patients.TNC <8 
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Methods: A prospective studywas conducted to characterize
the pharmacokinetics (PK) of ﬂudarabine plasma (f-ara-A)
and intracellular triphosphate (f-ara-ATP) in children
undergoing alloHCT and receiving ﬂudarabine with their
conditioning regimen. Plasma and peripheral blood mono-
nuclear cells (PBMCs) were collected over the 3-5 days of
ﬂudarabine treatment for quantitation of f-ara-A and f-ara-
ATP, respectively, using a validated liquid chromatography/
tandem mass spectrometry assay. Nonlinear mixed effects
modeling was used to develop the population PK model,
including identiﬁcation of covariates that inﬂuenced drug
disposition.
Results: Fifty-four children (median age 2 years, range 0.25-
17) undergoing alloHCT for a variety of malignant and
nonmalignant disorders underwent PK assessments. A 2-
compartment model with linear elimination best described
the PK of f-ara-A while a third compartment representing
PBMCs linked f-ara-A to f-ara-ATP. Final parameter estimates
and relative standard errors for f-ara-A are as follows:
clearance, 5.8 L/h (5.4%), volume of central compartment,
16.6 L (9.0%), volume of peripheral compartment, 16.6 L
(5.8%), and intercompartmental clearance, 3.0 L/h (14.1%).
Covariates signiﬁcantly impacting f-ara-A clearance included
body weight, age, and creatinine clearance (CrCL). Dose-
normalized PK exposure was highest among very small,
young children or subjects with renal dysfunction. Predicted
f-ara-A clearancewas reduced 40% in subjects with CrCL 50
mL/min compared to those with normal renal function (120
mL/min). Additionally, the rate of f-ara-A into PBMCs and/or
transformation to f-ara-ATP (modeled with a ﬁrst order rate
constant) decreased over the course of therapy, resulting in
42% lower intracellular f-ara-ATP exposure following the
third versus ﬁrst dose.
Impact: These results will help inform better dosing strate-
gies for ﬂudarabine, particularly in young infants with small
body size or in children with pre-existing renal dysfunction.
Re-evaluation of the optimal dosing regimen for ﬂudarabine
is warranted given the decrease in intracellular exposure to f-
ara-ATP with time.12
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AlloPBHCT compared to bone marrow transplants have a
decreased time to engraftment due to higher levels of CD34+
cells in the graft. However, the correlation of CD34+, CD3+,
CD4+, CD8+ and total nucleated cell (TNC) dose with out-
comes after alloPBHCT have been inconsistent. We retro-
spectively analyzed graft cell composition, focusing on
conditioning regimen intensity +/- total body irradiation
(TBI), in 254 consecutive ﬁrst alloPBHCT patients from 1/
2001 to 9/2012. Patient characteristics are: 58% male, 76%
40 years, 56% related/44% unrelated donor, 44% AML, 18%
MDS/MPD, 13% ALL, 13% NHL, 12% other diseases, 49% in CR
pre-PBHCT. 94 patients hadmyeloablative (MA) conditioning
with (n¼53) or without (n¼41) TBI. 160 patients had reduced
